Public Employees Retirement Association of Colorado lessened its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 0.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 298,027 shares of the biopharmaceutical company’s stock after selling 616 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Bristol-Myers Squibb were worth $15,113,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Garrett Wealth Advisory Group LLC bought a new position in shares of Bristol-Myers Squibb during the third quarter valued at approximately $26,000. Lenox Wealth Advisors LLC raised its holdings in shares of Bristol-Myers Squibb by 555.7% during the third quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 539 shares in the last quarter. Financial Gravity Wealth Inc. raised its holdings in shares of Bristol-Myers Squibb by 101.2% during the third quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 327 shares in the last quarter. 1 North Wealth Services LLC bought a new position in shares of Bristol-Myers Squibb during the third quarter valued at approximately $41,000. Finally, Endurance Wealth Management Inc. raised its holdings in shares of Bristol-Myers Squibb by 119.6% during the second quarter. Endurance Wealth Management Inc. now owns 918 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 500 shares in the last quarter. 80.40% of the stock is owned by hedge funds and other institutional investors.
In other news, insider Louis S. Schmukler sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the completion of the transaction, the insider now directly owns 31,963 shares in the company, valued at $1,807,827.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP John E. Elicker sold 15,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total value of $849,900.00. Following the transaction, the senior vice president now owns 74,471 shares of the company’s stock, valued at $4,219,526.86. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by corporate insiders.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.06 by $0.11. The business had revenue of $6.01 billion during the quarter, compared to the consensus estimate of $5.89 billion. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.09 earnings per share. On average, equities research analysts predict that Bristol-Myers Squibb Co will post 4.33 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 4th were issued a $0.41 dividend. The ex-dividend date of this dividend was Thursday, October 3rd. This represents a $1.64 dividend on an annualized basis and a yield of 2.82%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.
BMY has been the subject of a number of recent analyst reports. ValuEngine downgraded Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a report on Friday, October 25th. Wolfe Research set a $66.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a report on Friday, November 1st. Bank of America initiated coverage on Bristol-Myers Squibb in a report on Wednesday, October 16th. They set a “buy” rating and a $60.00 target price for the company. Peel Hunt restated a “buy” rating on shares of Bristol-Myers Squibb in a report on Tuesday, October 29th. Finally, TheStreet upgraded Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a report on Wednesday, September 18th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $56.64.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Story: Benefits of owning preferred stock
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.